0001209191-22-034551.txt : 20220606 0001209191-22-034551.hdr.sgml : 20220606 20220606164804 ACCESSION NUMBER: 0001209191-22-034551 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220603 FILED AS OF DATE: 20220606 DATE AS OF CHANGE: 20220606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jooss Karin CENTRAL INDEX KEY: 0001754280 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36076 FILM NUMBER: 22998662 MAIL ADDRESS: STREET 1: C/O GRITSTONE ONCOLOGY, INC. STREET 2: 5858 HORTON STREET, SUITE 210 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FATE THERAPEUTICS INC CENTRAL INDEX KEY: 0001434316 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 651311552 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 BUSINESS PHONE: 858.875.1803 MAIL ADDRESS: STREET 1: 12278 SCRIPPS SUMMIT DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92131 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-03 0 0001434316 FATE THERAPEUTICS INC FATE 0001754280 Jooss Karin C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 1 0 0 0 Common Stock 2022-06-03 4 S 0 1483 22.82 D 1198 D Required number of shares sold by the reporting person to cover tax obligations in connection with the vesting of 2,681 shares of Common Stock underlying RSUs granted to the reporting person on June 2, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Represents the weighted average sale price of the shares sold from $22.53 to $22.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. /s/ Cindy Tahl, as Attorney-in-Fact 2022-06-06